On the stock market since 2020, it operates in the world of health and science. It has 721 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 38% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 6 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $8.3M a year. A small number, but proof the product has real buyers.
There is $4.3B in the vault; even if every debt were paid off, $4.2B would remain.
A loss of $299.8M against $8.3M in annual sales. And on top of that, sales fell from the year before.
The sales tempo runs behind the sector. Council score: 2/10.
No clear buy-side message is coming from the executive floor. Council score: 3/10.
On our five-subject report card, ROIV sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ROIV is a high-risk stock — not yet profitable, and its future rides on its product catching on.